Who are BONCRESA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DMAB Discontinuation and Switching, Denosumab Prefilled Syringe [Prolia], Denosumab De-escalation, Romosozumab followed by Denosumab, Denosumab (Prolia), Romosozumab and Denosumab Cycle Therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/denosumab-mobz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BONCRESA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BONCRESA (DENOSUMAB-MOBZ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANK Ligand Inhibitor [EPC]. Area: Other.

marketed RANK Ligand Inhibitor [EPC] RANKL Other Live · refreshed every 30 min

Target snapshot

BONCRESA (DENOSUMAB-MOBZ) — AMNEAL PHARMS LLC. Denosumab binds to RANKL, preventing it from activating RANK on osteoclasts, reducing bone resorption and increasing bone mass.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BONCRESA TARGET	DENOSUMAB-MOBZ	AMNEAL PHARMS LLC	marketed	RANK Ligand Inhibitor [EPC]	RANKL
DMAB Discontinuation and Switching	DMAB Discontinuation and Switching	University of Alabama at Birmingham	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab Prefilled Syringe [Prolia]	Denosumab Prefilled Syringe [Prolia]	Seoul National University Bundang Hospital	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab De-escalation	Denosumab De-escalation	National Taiwan University Hospital	marketed	RANKL inhibitor monoclonal antibody de-escalation strategy	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Romosozumab followed by Denosumab	Romosozumab followed by Denosumab	National Taiwan University Hospital	marketed	Sclerostin inhibitor followed by RANKL inhibitor	Sclerostin (romosozumab); RANKL (Denosumab)
Denosumab (Prolia)	Denosumab (Prolia)	Prince of Wales Hospital, Shatin, Hong Kong	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (receptor activator of nuclear factor kappa-B ligand)
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANK Ligand Inhibitor [EPC] class)

AMNEAL PHARMS LLC · 1 drug in this class
Amgen · 1 drug in this class
SANDOZ INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BONCRESA — Competitive Intelligence Brief. https://druglandscape.com/ci/denosumab-mobz. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing